Personal Care Products · Nasdaq
IPARInterparfums Inc
- Last close
- $133.37 +2.0%
- 52-week range
- $77.21 to $138.13
- Market cap
- $4.27B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Revenue
$1.49B
+2% vs FY24
Net income
$168M
+2% vs FY24
Free cash flow
$190M
+4% vs FY24
Net cash
n/a
Book value at year end
Stock price
Valuation vs its own 10 years
Below its 10-year median on 1 of 4 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
P/E, trailing
25.1x
16.2x67.6x
20th percentile, below its median of 31.9x
Price / sales
2.8x
0.0x12,235x
62nd percentile, above its median of 2.2x
EV / EBITDA
14.6x
9.8x47.5x
89th percentile, above its median of 12.8x
Price / free cash flow
17.5x
0.0x139,894x
56th percentile, above its median of 15.4x
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 25.1x
- Earnings yield
- 4.0%
- Price / sales
- 2.8x
- Price / book
- 4.9x
- Price / operating cash flow
- 17.2x
- EV / EBITDA
- 14.6x
- EV / sales
- 2.9x
- Free cash flow yield
- 5.7%
Profitability
- Gross margin
- 64.8%
- Operating margin
- 17.9%
- Net margin
- 11.3%
- Return on equity
- 19.4%
- Return on capital
- 19.0%
Growth per year
- Revenue, 3 years
- +11.1%
- Revenue, 5 years
- +22.5%
- Revenue, 9 years
- +12.4%
- EPS, 3 years
- +11.5%
Balance sheet
- Cash and investments
- $184M
- Total debt
- $194M
- Net cash
- -$11.0M
- Debt / equity
- 0.22x
- Current ratio
- 3.33x
Shares and dividend
- Shares outstanding
- 32.0M
- Share count, 5 years
- +1.5%
- Beta, 1 year
- 0.05
- Dividend yield
- 2.4%
- Dividend per share, TTM
- $3.20
- Payout ratio
- 60.2%
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Revenue and net incomeLatest quarter $430M
RevenueNet income
Gross profitLatest quarter $288M
EBITDALatest quarter $124M
Margins67 / 27 / 16%
GrossOperatingNet
Earnings per shareLatest quarter $2.13
Cash flowLatest quarter $56.7M
OperatingCapexFree
Cash vs debtLatest quarter $184M
Cash and investmentsTotal debt
P/E historyNow 25.1x
P/E, median 31.9x dashed
P/S historyNow 2.8x
P/S, median 2.2x dashed
Revenue and net incomeFY25 $1.49B
RevenueNet income
Gross profitFY25 $947M
EBITDAFY25 $296M
Margins64 / 18 / 11%
GrossOperatingNet
Earnings per shareFY25 $5.24
Cash flowFY25 $215M
OperatingCapexFree
Cash vs debtFY25 $256M
Cash and investmentsTotal debt
P/E historyNow 25.1x
P/E, median 31.9x dashed
P/S historyNow 2.8x
P/S, median 2.2x dashed
Where the revenue comes from
Asia Pacific went from 15% to 13% of revenue in 3 years
Share of revenue by region, fiscal 2022 to 2025, as reported in the 10-K.
FY22
$1.09B
FY23
$1.32B
FY24
$1.45B
FY25
$1.49B
| Region | Revenue | Share | vs FY24 |
|---|---|---|---|
| North America | $557M | 37.4% | +3% |
| Western Europe | $383M | 25.7% | +5% |
| Asia Pacific | $189M | 12.7% | -4% |
| Eastern Europe | $121M | 8.1% | +2% |
| Central and South America | $121M | 8.1% | +11% |
| Middle East and Africa | $118M | 7.9% | -4% |
Personal Care Products peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| EL Estee Lauder Companies Inc | $40.9B | +6% | 6.7% | 111x | 2.7x | 88th percentile |
| KVUE Kenvue Inc. | $37.1B | +3% | 17.4% | 21.9x | 2.4x | 29th percentile |
| ELF e.l.f. Beauty, Inc. | $6.98B | +40% | 8.9% | 81.4x | 3.6x | 69th percentile |
| IPAR Interparfums Inc | $4.27B | +3% | 17.9% | 25.1x | 2.8x | 20th percentile |
| COTY Coty Inc. | $3.56B | -0% | -1.7% | No earnings | 0.6x | No earnings |
| HLF Herbalife Ltd. | $1.67B | +6% | 9.6% | 9.5x | 0.3x | 42nd percentile |
The company
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Headquarters
- New York, NY
- Fiscal year ends
- December
Around the numbers
What the rest of EdgeStacker knows about IPAR.